Please assess the completion status of the following clinical trial:

Trial Title: A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 15.0

Eligibility Criteria:
Key Inclusion Criteria:~Parts A, B, and C:~* Female subjects must be of non-childbearing potential.~* Between the ages of 18 and 55 years, inclusive.~* Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight \>50 kg~Parts D, E, and F:~* Body weight ≥35 kg.~* Subjects must have an eligible CFTR genotype:~  * Parts D and F: Heterozygous for F508del and an MF mutation (F/MF)~ * Part E: Homozygous for F508del (F/F)~* FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height.~Key Exclusion Criteria:~Parts A, B, and C:~* Any condition possibly affecting drug absorption.~* History of febrile illness within 14 days before the first study drug dose.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency.~Parts D, E, and F:~* History of clinically significant cirrhosis with or without portal hypertension.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency.~* Lung infection with organisms associated with a more rapid decline in pulmonary status.~* History of solid organ or hematological transplantation.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part A: Pooled Placebo (Except Cohort A7) (Type: PLACEBO_COMPARATOR): Participants without CF who received single dose of placebo matched to VX-445 in Cohort A1 to A5.
- Part A: VX-445 (Except Cohort A7) (Type: EXPERIMENTAL): Participants without CF who received single ascending dose of VX-445 tablet starting from 20 milligrams (mg) to 360 mg in Cohort A1 to A5.
- Part A: VX-445 (Cohort A7) (Type: EXPERIMENTAL): Participants without CF who received single dose of VX-445 100 mg tablet on Day 1 in fasted state and on Day 7 in fed state, followed by VX-445 20 mg intravenous (IV) injection on Day 13 in fed state in Cohort A7.
- Part B: Pooled Placebo (Cohort B1 to B4) (Type: PLACEBO_COMPARATOR): Participants without CF who received multiple doses of placebo matched to VX-445 once daily (qd) for 10 days in Cohort B1 to B4.
- Part B: VX-445 (Cohort B1 to B4) (Type: EXPERIMENTAL): Participants without CF who received VX-445 tablet qd for 10 days in Cohort B1 (60 mg), B2 (120 mg), B3 (240 mg) and B4 (340 mg).
- Part C: Pooled Placebo (Cohort C1 to C3) (Type: PLACEBO_COMPARATOR): Participants without CF who received placebo matched to VX-445/TEZ/IVA triple combination (TC) qd in the morning and placebo matched to IVA in the evening for 14 days.
- Part C: VX-445/TEZ/IVA TC (Cohort C1 to C3) (Type: EXPERIMENTAL): Participants without CF who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C1; VX-445 280 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C2 and VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in Cohort C3 for 14 days.
- Part D: Placebo (Type: PLACEBO_COMPARATOR): Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/IVA TC qd in the morning and placebo matched to IVA qd in the evening for 4 weeks in the TC treatment period.
- Part D: VX-445/TEZ/IVA TC - Low Dose (Type: EXPERIMENTAL): Participants with CF, F/MF genotype who received VX-445 50 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
- Part D: VX-445/TEZ/IVA TC - Medium Dose (Type: EXPERIMENTAL): Participants with CF, F/MF genotype who received VX-445 100 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
- Part D: VX-445/TEZ/IVA TC - High Dose (Type: EXPERIMENTAL): Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the TC treatment period.
- Part E: TEZ/IVA (Type: ACTIVE_COMPARATOR): Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received TEZ 100 mg qd/IVA 150 mg q12h and placebo matched to VX-445 for 4 weeks in the TC treatment period.
- Part E: VX-445/TEZ/IVA TC (Type: EXPERIMENTAL): Following run-in period of 4 weeks with TEZ/IVA, participants with CF, F/F genotype who received VX-445 200 mg qd/TEZ 100 mg qd /IVA 150 mg q12h for 4 weeks in the TC treatment period.
- Part F: Placebo (Type: PLACEBO_COMPARATOR): Participants with CF, F/MF genotype who received placebo matched to VX-445/TEZ/VX-561 for 4 weeks in the TC treatment period.
- Part F: VX-445/TEZ/VX-561 TC (Type: EXPERIMENTAL): Participants with CF, F/MF genotype who received VX-445 200 mg qd/TEZ 100 mg qd/VX-561 150 mg qd for 4 weeks in the TC treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete